Fig. 6

Blocking IL-17A suppressed tumor growth in vitro but reduced the efficacy of anti-PD-1 therapy in vivo by decreasing PD-L1 protein expression. A Schematic diagram of the establishment of animal subcutaneous tumor model. B–D Tumor volume and weight of mice in control group, anti-IL-17 monoclonal antibody treatment group, anti-PD-L1 monoclonal antibody treatment group, and anti-IL-17A combined with anti-PD-L1 treatment group. E Changes in body weight of mice in 4 groups after drug intervention. F Immunohistochemistry was used to detect the expression levels of LC3, p62, Nrf2 and PD-L1 in tumor tissues. *p < 0.05, **p < 0.01, ***p < 0.001, indicating statistically significant difference